VRTX

Vertex Pharmaceuticals
D

VRTX

Arincen81/100B

Vertex Pharmaceuticals executives and insider trading

Reshma Kewalramani FASN reported no open-market purchases or sales over the last twelve months.

Over the last twelve months Vertex Pharmaceuticals's insiders sold 337,299 shares for 155.74M USD in 91 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
91
Shares sold
337,299
Value sold
155.74M USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
0
0
1 month
0
0
3 months
0
0
6 months
10.04M USD
0
1 year
155.74M USD
5.84M USD
2 years
176.83M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Jeffrey Marc Leiden Executive Chairman70137,07360.94M USD—3 Dec 202534,797
Amit K. Sachdev Executive Vice President & Chief Patient and External Affairs Officer5856,22226.38M USD—25 Feb 202666,512
Reshma Kewalramani Director, CEO & President—40,00019.74M USD—27 Feb 2026137,878
Carmen Bozic Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer6324,72611.31M USD—26 Jun 202615,337
Charles F. Wagner Jr. Executive Vice President, Chief Operating Officer & Chief Financial Officer5823,53210.78M USD—6 Jan 202647,042
Ourania Tatsis Executive VP & Chief Product Affairs Officer5613,7036.51M USD—2 Jul 202653,572
Duncan Mckechnie EVP, Chief Commercial Officer—11,5215.66M USD—2 Jul 202611,001
Jonathan Biller EVP and Chief Legal Officer—7,9253.80M USD—25 Feb 202613,659
Edward Morrow Iii Atkinson EVP, Chief Technical Ops. Off.—7,7673.60M USD—25 Feb 202618,432
Mark E. Bunnage EVP, Chief Scientific Officer—6,2933.00M USD—15 May 20267,284
Kristen C. Ambrose Senior Vice President & Chief Accounting Officer504,1511.98M USD—26 Feb 202611,624
Joy Liu EVP, Chief Legal Officer & Corporate Secretary483,8021.77M USD—1 Jul 202619,131
Sangeeta N. Bhatia Director—584267.75K USD—4 May 20264,924

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
2 Jul 2026Ourania TatsisSale1,500524.99787.49K USD45,321Form 4
2 Jul 2026Duncan MckechnieSale1,541519.00799.78K USD11,001Form 4
1 Jul 2026Joy LiuSale828502.71416.24K USD19,131Form 4
26 Jun 2026Carmen BozicSale596482.50287.57K USD15,337Form 4
18 Jun 2026Carmen BozicSale1,020462.17471.41K USD15,933Form 4
15 Jun 2026Carmen BozicSale4,062450.001.83M USD16,953Form 4
5 Jun 2026Carmen BozicSale1,745450.00785.25K USD21,015Form 4
29 May 2026Carmen BozicSale1,974450.00888.30K USD22,760Form 4
15 May 2026Mark E. BunnageSale33453.4514.96K USD7,284Form 4
15 May 2026Carmen BozicSale1,354453.45613.97K USD24,734Form 4
12 May 2026Carmen BozicSale6,988450.003.14M USD26,088Form 4
4 May 2026Sangeeta N. BhatiaSale318423.73134.75K USD4,924Form 4
1 May 2026Joy LiuSale1,104425.02469.22K USD20,729Form 4
1 Apr 2026Joy LiuSale978449.17439.29K USD21,833Form 4
27 Mar 2026Carmen BozicSale2,329450.951.05M USD33,076Form 4

Common questions about Vertex Pharmaceuticals's executives and insiders

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.